Related Experiment Videos
Decrease in the number of neonatal islets required for successful transplantation by strict metabolic control of
A Hayek1, A D Lopez, G M Beattie
1Lucy Thorne Children's Center, Whittier Institute for Diabetes and Endocrinology, La Jolla, California 92037.
Transplantation
|May 1, 1988
Summary
Improving glycemic control significantly reduces the number of neonatal islets required for curing streptozotocin-induced diabetes in rats. Normalizing blood glucose levels pre-transplant leads to a 100% cure rate.
Area of Science:
- Endocrinology
- Regenerative Medicine
- Transplantation Biology
Background:
- Streptozotocin (STZ)-induced diabetes in rats serves as a model for type 1 diabetes.
- Neonatal islets are a potential source for islet transplantation, but their efficacy compared to adult islets is debated.
- Optimizing the recipient's metabolic state is crucial for successful islet transplantation outcomes.
Purpose of the Study:
- To investigate the impact of glycemic control on the efficacy of intrasplenic neonatal islet transplantation in STZ-diabetic rats.
- To determine the minimum number of neonatal islets required for diabetes remission under varying glycemic conditions.
- To compare the therapeutic potential of neonatal islets with adult islets in a preclinical model.
Main Methods:
- Induction of diabetes in rats using streptozotocin (STZ).
- Intrasplenic transplantation of neonatal islets into diabetic rats with differing glycemic control levels.
- Administration of insulin post-transplantation to modulate glycemic control.
- Assessment of cure rates based on normalization of blood glucose levels.
Main Results:
- Intrasplenic transplantation of 1000 neonatal islets cured only 30% of STZ-diabetic rats with poor glycemic control.
- Post-transplant insulin therapy (10-15 U/day for 5 days) improved the cure rate to 72%.
- Prior normalization of blood glucose via kidney capsule transplantation resulted in a 100% cure rate, despite adult islets showing superior in vitro characteristics.
Conclusions:
- Neonatal islets are a viable source for endocrine replacement therapy via intrasplenic transplantation.
- Normalization of the recipient's metabolic milieu, particularly blood glucose levels, significantly enhances the success of islet transplantation.
- The number of islets needed for a cure is substantially reduced when the recipient's glycemic control is optimized prior to or following transplantation.